Euroapi SA Earnings Call: Discipline Amid Declining Sales

Euroapi SA ((FR:EAPI)) has held its Q4 earnings call. Read on for the main highlights of the call.

Euroapi SA’s latest earnings call painted a mixed picture, blending solid progress in cash generation, cost control, and portfolio quality with heavy revenue pressure, large impairments, and a widening net loss. Management stressed that the company is more disciplined and resilient, yet acknowledged that near‑term growth will be weak and some key 2027 targets will no longer be met.

Profitability Rebound: Core EBITDA and Margins Climb

Euroapi’s core EBITDA jumped 31% to EUR 66.2 million in 2025, lifting the core margin to 7.8% from 5.5% a year earlier. Reported EBITDA swung back into positive territory at around EUR 10 million, a sharp improvement from the EUR 44 million loss recorded in 2024, signalling healthier underlying operations despite the revenue decline.

Cash Generation Strengthens Net Cash Fortress

Operating cash flow surged to EUR 128.5 million in 2025, while free cash flow before financing more than tripled to EUR 51.5 million versus EUR 15.0 million in 2024. This strong cash performance allowed Euroapi to end the year with a net cash position of EUR 68.2 million, up from EUR 24.6 million, reinforcing its financial flexibility in a volatile backdrop.

Working Capital Unlocks Significant Liquidity

Working capital management was a standout contributor, generating EUR 120.1 million of cash flow over the year. The company reduced inventories by EUR 38.9 million and trimmed trade receivables by EUR 45.4 million, including EUR 26.5 million of factoring, bringing months on hand to 7 and days sales outstanding to 36, a clear sign of tighter operational control.

Cost Discipline and Restructuring Deliver Savings

Euroapi highlighted sustained OpEx discipline, with roughly EUR 20 million of operating expense savings delivered over the last two years. Around 380 positions have been removed as part of footprint and organizational simplification, underpinning the margin improvement but also reflecting the depth of the ongoing transformation.

CapEx Tightened but Focused on Growth Niches

Investment spending has been reined in, with CapEx at EUR 77 million in 2025, about 9% of net sales and well below the EUR 108 million and EUR 137 million spent in 2024 and 2023. Importantly, around 65% of 2025 CapEx was channelled into growth and performance projects such as peptides, oligonucleotides, prostaglandins, and corticosteroids, aiming to tilt the portfolio toward higher‑value APIs.

Sustainability Targets Gain External Validation

On the ESG front, Euroapi’s near‑term carbon reduction goals were validated by the Science Based Targets initiative, giving external credibility to its climate roadmap. The company reported that it has already achieved about half of its targeted Scope 1 and 2 emissions cuts and has surpassed its Scope 3 objective, positioning sustainability as a strategic differentiator in its markets.

Portfolio Upgrading and FOCUS‑27 Execution

Management underlined progress in upgrading portfolio quality, with differentiated products accounting for 66% of 2025 sales, up from 57% at the end of 2023 and moving toward a 70% target by 2027. The CDMO pipeline has also shifted toward later‑stage projects, with roughly 70% in late development, while disposals such as the Haverhill site and industrial consolidation moves support the FOCUS‑27 restructuring plan.

Lower Financing Costs Ease Bottom‑Line Pressure

Financial expenses provided a rare bright spot, with net financial costs improving by EUR 7.5 million versus 2024 after a refinancing and broader financing plan. The reported cost of debt has dropped to around EUR 3 million, meaning less drag on earnings even as operating performance remains under pressure.

Sales Contraction and Sanofi Exposure Reset

Despite the operational gains, the top line weakened, with net sales slipping 7% to EUR 848.2 million in 2025, or 5.9% on a comparable basis. A major driver was the sharp downsizing of business with Sanofi, where total sales fell 26.4% and API solutions to Sanofi dropped 34.2%, leaving the group less concentrated but battling significant immediate revenue loss.

Portfolio Rationalization to Weigh Heavily on 2026

The deliberate discontinuation of certain API product lines removed roughly EUR 70 million of sales in 2025, including about EUR 20 million of stockpiling. Management expects only EUR 10–15 million of residual revenue from these products in 2026, implying a EUR 55–60 million headwind and confirming that portfolio pruning, while strategic, will continue to cap near‑term growth.

Net Loss Deepens as Impairments Mount

Euroapi’s bottom line deteriorated sharply, with net loss widening to EUR 211.2 million in 2025 from EUR 130.6 million in 2024. Asset impairments rose to EUR 77.8 million, largely tied to the discontinuation of the vitamin B12 project and a reassessment of its economic potential, underscoring the cost of exiting low‑margin or structurally challenged activities.

Transformation Costs and Idle Assets Hit Results

Nonrecurring items totalled EUR 56.3 million in 2025, reflecting the depth of the restructuring underway. This included EUR 36.1 million of idle costs, mainly linked to the Frankfurt site, and EUR 13.7 million of employee‑related expenses tied to redundancies, with management signalling a sizeable cash restructuring envelope earmarked for the next two years.

CDMO Weakness and Missed Growth Ambitions

The contract development and manufacturing business disappointed, with CDMO sales to other clients falling 13.6% amid downsizing and a slowdown in early‑stage activity. Management now concedes that the previously targeted incremental core EBITDA by 2027 under the FOCUS‑27 plan will not be achieved on the original timetable, a setback for the growth narrative that had been anchored in CDMO expansion.

Asian Competition Forces Strategic Retreats

Competitive pressure from low‑cost Asian producers intensified, particularly in commodity APIs such as vitamin B12, eroding prices and margins in exposed product lines. This dynamic contributed directly to strategic discontinuations and impairments, and it reinforces Euroapi’s broader pivot away from commoditized volumes toward more differentiated and technologically complex molecules.

Social and Safety Metrics Lag Transformation Pace

Beyond the financials, Euroapi reported that some operational and social key performance indicators fell short of 2025 objectives, notably diversity targets, which were hit by the reorganization even though prior trends had been positive. Safety performance also failed to improve, with injury rates broadly stable, prompting the rollout of a new Accident Prevention Plan in 2026 as management tries to realign people metrics with strategic ambitions.

CapEx Uncertainties and Risk of Further Impairments

While capital discipline remains a stated priority, the company has already spent EUR 185 million of an originally planned EUR 350–400 million CapEx envelope for 2024–2027. Management signalled that the remaining project pipeline may need optimization and left the door open to potential future impairments or adjustments, adding another layer of uncertainty for investors tracking long‑term returns on invested capital.

Outlook: Flat Margins Amid Deliberate Revenue Decline

For 2026, Euroapi reiterated that net sales are expected to decline by about 10% on a comparable basis, with roughly 90% of the drop stemming from its own portfolio rationalization and the residual impact of discontinued SKUs. The group aims to keep the core EBITDA margin roughly flat versus 2025’s 7.8%, target CapEx at around 8% of sales, and absorb about EUR 100 million of cash restructuring costs over 2026–27, while acknowledging that its original FOCUS‑27 EBITDA ambitions will not be reached on time.

Euroapi’s earnings call underscored a company in full restructuring mode, trading short‑term revenue and headline earnings for better cash flow, stronger balance sheet metrics, and a more defensible product mix. For investors, the story now hinges on whether management can sustain margin improvements and complete the portfolio shift before competitive and restructuring headwinds erode the benefits of today’s tighter financial discipline.